Pharmacovigilance

The foundational data collection process where individual case safety reports (ICSRs) are submitted by healthcare professionals, patients, and pharmaceutical companies to regulatory authorities.

• Spontaneous Reporting: Unsolicited communications describing suspected adverse drug reactions
• Solicited Reports: Data derived from organized data collection systems like patient registries
• Expedited Reporting: Mandatory 15-day reporting for serious and unexpected adverse events

Modern systems use natural language processing to extract structured data from unstructured clinical narratives.

The systematic process of identifying previously unknown or incompletely documented causal relationships between drugs and adverse events from aggregated safety data.

• Disproportionality Analysis: Statistical methods like PRR (Proportional Reporting Ratio) and ROR (Reporting Odds Ratio) that quantify unexpected reporting frequencies
• Bayesian Methods: Advanced techniques including the Multi-Item Gamma Poisson Shrinker (MGPS) used by the FDA
• Sequential Probability Ratio Testing: Continuous monitoring approaches that adjust for multiple looks at accumulating data

Signal detection distinguishes true safety signals from background noise in spontaneous reporting databases.

A structured set of pharmacovigilance activities designed to characterize, minimize, and communicate the risks of a medicinal product throughout its lifecycle.

• Risk Evaluation and Mitigation Strategies (REMS): FDA-mandated programs that may include restricted distribution, provider certification, or patient monitoring
• Risk Management Plans (RMPs): EU-required documents outlining routine and additional pharmacovigilance activities
• Post-Authorization Safety Studies (PASS): Non-interventional studies conducted after market approval to investigate specific safety concerns

Effective risk management balances therapeutic benefit against potential harm using the benefit-risk ratio framework.

Comprehensive PSURs are legally mandated documents that provide an evaluation of the benefit-risk balance of a medicinal product at defined time points during the post-authorization phase.

• Cumulative Safety Review: Analysis of all adverse events since the international birth date
• Exposure Data: Estimation of patient exposure using sales volume and defined daily doses
• Integrated Benefit-Risk Assessment: Structured evaluation using frameworks like BRAT (Benefit-Risk Action Team) methodology

PSURs follow the ICH E2C(R2) guideline format and are submitted to regulatory authorities on a harmonized schedule.

Systematic, independent examinations of pharmacovigilance activities to determine whether safety processes comply with regulatory requirements and internal standard operating procedures.

• Pharmacovigilance System Master File (PSMF): A detailed description of the global pharmacovigilance system maintained by the marketing authorization holder
• Key Performance Indicators (KPIs): Metrics including case processing timeliness, submission compliance, and signal detection throughput
• Corrective and Preventive Actions (CAPA): Structured remediation plans addressing audit findings

Regulatory inspections by the FDA, EMA, and MHRA can result in warning letters or product withdrawal for systemic non-compliance.

A systematic process of screening global biomedical literature to identify published case reports and studies containing potential adverse drug reaction information.

• Global Literature Screening: Weekly or biweekly searches of databases including PubMed, Embase, and local language journals
• ML-Assisted Triage: Machine learning classifiers that prioritize articles for human review based on relevance scoring
• Product-Specific Surveillance: Targeted monitoring for marketed products using proprietary search strings

Marketing authorization holders must report literature-identified cases from both indexed and non-indexed journals to maintain global compliance.

A noxious and unintended response to a medicinal product occurring at doses normally used in humans for prophylaxis, diagnosis, or therapy. ADRs are classified into Type A (augmented, dose-dependent, predictable) and Type B (bizarre, idiosyncratic, unpredictable) reactions. The WHO-UMC causality assessment system categorizes ADRs as certain, probable, possible, unlikely, conditional/unclassified, or unassessable based on temporal relationship, dechallenge, rechallenge, and alternative explanations.

The process of identifying previously unknown or incompletely documented potential causal associations between a drug and an adverse event. Modern signal detection employs disproportionality analysis methods including:

• PRR (Proportional Reporting Ratio): Compares observed vs. expected reporting frequency
• ROR (Reporting Odds Ratio): Case/non-case analysis within spontaneous reporting databases
• Bayesian Confidence Propagation Neural Network (BCPNN): Used by WHO-UMC for the VigiBase global database
• MGPS (Multi-item Gamma Poisson Shrinker): Employed by FDA for FAERS database mining

Passive surveillance systems where healthcare professionals, patients, and manufacturers voluntarily submit suspected ADR reports to regulatory authorities. Key global systems include the FDA Adverse Event Reporting System (FAERS) in the US, EudraVigilance in the EU, and VigiBase maintained by the WHO Uppsala Monitoring Centre. These systems form the backbone of post-marketing surveillance but suffer from under-reporting (estimated at 1-10% of actual ADRs), reporting biases, and lack of denominator data for incidence calculation.

The standardized format for reporting a suspected adverse event associated with a medicinal product to regulatory authorities. An ICSR must contain four minimum criteria for a valid report:

• Identifiable patient: Age, sex, initials, or medical record identifier
• Identifiable reporter: Healthcare professional or consumer contact details
• Suspected drug: Specific medicinal product name and dosage information
• Adverse event: Description of the reaction with temporal relationship

The ICH E2B(R3) standard defines the electronic transmission format using XML schema and controlled terminologies like MedDRA for event coding.